NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
Karyopharm Therapeutics Inc
Fred Hutchinson Cancer Center
University of California, Davis
Radiation Therapy Oncology Group
Duke University
University College, London
Isarna Therapeutics GmbH